Similarly, in a previous phase II study of elderly Japanese patients treated with afatinib, pneumonitis was reported in four (10%) patients, one of whom had grade 3 pneumonitis and two of whom died whilst on treatment, suggesting that elderly patients treated with an EGFR-TKI should be monitored for pneumonitis [18]. This evidence concerns the gene EGFR and pneumonitis.